Drug Profile
Research programme: antibody therapeutics - TaiMed Biologics
Alternative Names: TMB 360Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator Aaron Diamond AIDS Research Center
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action CD4 antigen inhibitors; HIV envelope protein gp120 inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in HIV-infections in Taiwan (Parenteral)
- 20 May 2016 TaiMed Biologics in-licenses TMB 365-relevant technology platform from the Aaron Diamond AIDS Research Center (before May 2016; TaiMed Biologics website, May 2016)
- 20 May 2016 Preclinical trials in HIV infections in Taiwan (Parenteral) (before May 2016; TaiMed Biologics pipeline, May 2016)